1 |
陈志敏,求伟玲. 儿童肺炎支原体肺炎治疗进展[J]. 中华实用儿科临床杂志,2021, 36(16): 1214-1217.
|
2 |
邹映雪. 肺炎支原体肺炎炎症指标异常的临床意义[J]. 中华实用儿科临床杂志,2021, 36(16):1209-1214.
|
3 |
Fujita J. Mycoplasma pneumoniae pneumonia and respiratory syncytial virus infection in Japan during the severe acute respiratory syndrome coronavirus 2 pandemic[J]. Respiratory Investigation, 2021, 59(1): 5-7.
|
4 |
范玉洁,俞怡雪,李玉琴,等. 儿童肺炎支原体肺炎中MP载量的临床意义及可能发病机制[J]. 临床肺科杂志,2021, 26(8): 1203-1207.
|
5 |
Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950[J]. Pharmacological Reviews, 2021, 73(3): 968-1000.
|
6 |
刘 丹,李玲霞,吴锦艳,等. NLRP3炎性小体及其调控机制研究进展[J]. 动物医学进展,2020, 41(12): 90-95.
|
7 |
胡 杨,刘春峰. 儿童肺炎支原体相关肺外并发症临床表现及发病机制[J]. 中国小儿急救医学,2021, 28(1): 7-11.
|
8 |
黄绍光,陈 巍. 肺炎支原体肺炎的诊断与治疗[J]. 医学临床研究,2003, 20(4): 277-278.
|
9 |
吴红梅,叶翠燕. 复方甘草酸苷联合布地奈德雾化治疗小儿肺炎支原体肺炎的疗效分析[J/CD]. 中华肺部疾病杂志,2022, 15(6): 850-852.
|
10 |
Krafft C, Christy C. Mycoplasma pneumonia in Children and adolescents[J]. Pediatrics in Review, 2020, 41(1): 12-19.
|
11 |
李 娜,朱 雄,程 远,等. MLKL-NLRP3炎症小体介导的坏死性炎症反应在脓毒症急性肺损伤小鼠中的作用及其机制[J]. 中华危重病急救医学,2021, 33(5): 523-528.
|
12 |
房有福,李 娜. 肺炎支原体肺炎NLRP3炎症小体通路的表达及意义[J]. 中国当代儿科杂志,2018, 20(9): 742-745.
|
13 |
丰依明,李智成,谢瑞芳,等. 麻杏石甘汤联合阿奇霉素治疗小儿支原体肺炎的系统评价[J]. 药物评价研究,2022, 45(4): 768-779.
|
14 |
张文风,姜梦雨. 麻杏石甘汤治疗疫病的证治探微[J]. 长春中医药大学学报,2022, 38(12): 1299-1302.
|
15 |
朱丽臻,石艳红,蔡小其. 麻杏石甘汤加减联合阿奇霉素治疗痰热闭肺型肺炎支原体肺炎患儿疗效观察及对IFN-γ、IL-4表达的影响[J]. 广州中医药大学学报,2020, 37(10): 1876-1880.
|
16 |
Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children[J]. J Microbiol Immunol Infect, 2021, 54(4): 557-565.
|
17 |
Zhou Y, Wang J, Chen W, et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2020, 20(1): 633.
|
18 |
Cao B, Qu JX, Yin YD, et al. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance[J]. Clin Respir J, 2017, 11(4): 419-429.
|
19 |
Lee H, Yun KW, Lee HJ, et al. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. Expert Rev Anti Infect Ther, 2018, 16(1): 23-34.
|
20 |
Chang CH, Tsai CK, Tsai TA, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan[J]. Pediatr Neonatol, 2021, 62(5): 536-542.
|
21 |
刘 军,石 颖,王婷婷,等. NLRP3的过度激活与ARDS和损伤性机械通气诱导的肺损伤的关系[J]. 中国医药导报,2021, 18(18): 17-21.
|
22 |
徐 梦,卢瑞萍,朱 丽,等. 外周血单核细胞中NLRP3 mRNA、Caspase-1 mRNA、IL-1β及IL-18表达水平与重症肺炎患者病情严重程度及预后的相关性分析[J]. 标记免疫分析与临床,2021, 28(7): 1110-1114, 1120.
|
23 |
朱晓晨,付迎新,赵淑青,等. 血清D-二聚体、IL-6、IL-18对儿童难治性肺炎支原体肺炎的预测价值[J]. 临床与病理杂志,2022, 42(2): 376-381.
|
24 |
姜之炎,阚倩娜. 清肺通络方对肺炎支原体肺炎TGF-β、IL-1β表达的影响[J]. 中华中医药杂志,2021, 36(11): 6731-6734.
|
25 |
刘 勇,刘 丹,柴文戍. 血IL-1β、IL-18、Eos水平与支气管哮喘急性发作病情程度的关系及对近期转归的预测效能探讨[J]. 东南大学学报:医学版,2022, 41(4): 464-470.
|
26 |
赵 婷,张芳菲,汪年松,等. NLRP3炎症小体作为肾脏疾病潜在治疗靶标的研究进展[J]. 中国临床医学,2022, 29(4): 685-695.
|
27 |
Oishi T, Yoshioka D, Nakano T, et al. Recent Trend of Antimicrobial Susceptibility among Mycoplasma pneumoniae Isolated from Japanese Children[J]. Microorganisms, 2022, 10(12): 2428.
|
28 |
Choo S, Kim SH, Lee E. Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2022, 22(1): 470.
|